Y-Prime LLC
, an enterprise consulting and eClinical products company, has established a systems integration partnership with
Veeva Systems
, a company in cloud-based business solutions for the global life sciences industry.
Together, the companies aim to provide global life sciences organizations with the tools to establish a content management solution as well as the ability to facilitate a smooth migration of legacy ECM platforms, such as Documentum and FirstDoc, to Veeva Vault in the cloud.
"Y-Prime has deep domain expertise in document management solutions..." explains Dan Glass, vice president of Enterprise Content Management at Y-Prime. "As global life sciences companies seek to migrate from expensive, legacy systems such as Documentum, our partnership with Veeva offers a path that integrates the change management, technical implementation and training expertise that will ensure a successful transition to the Vault Enterprise applications. For those companies that have not invested in ECM as yet," Dan continues, "our deep domain experience will play a significant role in helping companies to develop a strategy to fully realize the benefits of Vault Enterprise."
Veeva Systems recently announced Vault Enterprise, the first cloud-based suite of content management applications developed specifically for the global life sciences industry. Spanning every major part of a life sciences company - from R&D to clinical trials to manufacturing, medical communications and marketing - Vault Enterprise aims to give the pharmaceutical, biotechnology and medical products companies the ability to deploy a single technology solution globally. The results are faster implementations, dramatic cost savings and reduced regulatory risk.
"Y-Prime's knowledge of the legacy environments operating in this industry makes them well-suited to assist our customers in their moves to the cloud," says Jennifer Goldsmith, vice president of strategy, Veeva Vault at Veeva Systems. "Working together, we will help our clients reduce time to market and ensure regulatory compliance through the implementations of Vault Enterprise."
Global life sciences companies engage Y-Prime's ECM and eCTD practice team to develop transformative strategies combined with technical expertise in cloud transformation, externalization and harmonization as well as business process consulting. Y-Prime also provides eClinical systems consulting as well as a suite of cloud-based eClinical solutions; Prime IWRS, Prime eMVR, Prime ePRO and Prime Publisher.
Please visit Veeva (Booth 201) and Y-Prime (Booth 311) at the Drug Industry Association's EDM and ERS/eCTD Conference October 8-11 at the Hilton Baltimore.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.